474 related articles for article (PubMed ID: 27009601)
1. Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease.
Lastres-Becker I; García-Yagüe AJ; Scannevin RH; Casarejos MJ; Kügler S; Rábano A; Cuadrado A
Antioxid Redox Signal; 2016 Jul; 25(2):61-77. PubMed ID: 27009601
[TBL] [Abstract][Full Text] [Related]
2. The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-κB/Nuclear Transcription Factor Related to NF-E2.
Campolo M; Casili G; Biundo F; Crupi R; Cordaro M; Cuzzocrea S; Esposito E
Antioxid Redox Signal; 2017 Sep; 27(8):453-471. PubMed ID: 28006954
[TBL] [Abstract][Full Text] [Related]
3. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease.
Lastres-Becker I; Ulusoy A; Innamorato NG; Sahin G; Rábano A; Kirik D; Cuadrado A
Hum Mol Genet; 2012 Jul; 21(14):3173-92. PubMed ID: 22513881
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment with Korean red ginseng or dimethyl fumarate attenuates reactive gliosis and confers sustained neuroprotection against cerebral hypoxic-ischemic damage by an Nrf2-dependent mechanism.
Liu L; Vollmer MK; Ahmad AS; Fernandez VM; Kim H; Doré S
Free Radic Biol Med; 2019 Feb; 131():98-114. PubMed ID: 30458277
[TBL] [Abstract][Full Text] [Related]
5. Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.
Ahuja M; Ammal Kaidery N; Yang L; Calingasan N; Smirnova N; Gaisin A; Gaisina IN; Gazaryan I; Hushpulian DM; Kaddour-Djebbar I; Bollag WB; Morgan JC; Ratan RR; Starkov AA; Beal MF; Thomas B
J Neurosci; 2016 Jun; 36(23):6332-51. PubMed ID: 27277809
[TBL] [Abstract][Full Text] [Related]
6. Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate.
Belcher JD; Chen C; Nguyen J; Zhang P; Abdulla F; Nguyen P; Killeen T; Xu P; O'Sullivan G; Nath KA; Vercellotti GM
Antioxid Redox Signal; 2017 May; 26(14):748-762. PubMed ID: 26914345
[TBL] [Abstract][Full Text] [Related]
7. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity.
Jing X; Shi H; Zhang C; Ren M; Han M; Wei X; Zhang X; Lou H
Neuroscience; 2015 Feb; 286():131-40. PubMed ID: 25449120
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.
Cuadrado A; Kügler S; Lastres-Becker I
Redox Biol; 2018 Apr; 14():522-534. PubMed ID: 29121589
[TBL] [Abstract][Full Text] [Related]
9. Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.
Wang Q; Chuikov S; Taitano S; Wu Q; Rastogi A; Tuck SJ; Corey JM; Lundy SK; Mao-Draayer Y
Int J Mol Sci; 2015 Jun; 16(6):13885-907. PubMed ID: 26090715
[TBL] [Abstract][Full Text] [Related]
10. Effect of dimethyl fumarate on neuroinflammation and apoptosis in pentylenetetrazol kindling model in rats.
Singh N; Saha L; Kumari P; Singh J; Bhatia A; Banerjee D; Chakrabarti A
Brain Res Bull; 2019 Jan; 144():233-245. PubMed ID: 30472152
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of Dimethyl Fumarate Are Tissue Specific and Involve NRF2-Dependent and -Independent Mechanisms.
Brennan MS; Patel H; Allaire N; Thai A; Cullen P; Ryan S; Lukashev M; Bista P; Huang R; Rhodes KJ; Scannevin RH
Antioxid Redox Signal; 2016 Jun; 24(18):1058-71. PubMed ID: 26980071
[TBL] [Abstract][Full Text] [Related]
12. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
Gopal S; Mikulskis A; Gold R; Fox RJ; Dawson KT; Amaravadi L
Mult Scler; 2017 Dec; 23(14):1875-1883. PubMed ID: 28156185
[TBL] [Abstract][Full Text] [Related]
13. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model.
Gan L; Vargas MR; Johnson DA; Johnson JA
J Neurosci; 2012 Dec; 32(49):17775-87. PubMed ID: 23223297
[TBL] [Abstract][Full Text] [Related]
14. Role of microgliosis, oxidative stress and associated neuroinflammation in the pathogenesis of Parkinson's disease: The therapeutic role of Nrf2 activators.
Jayaram S; Krishnamurthy PT
Neurochem Int; 2021 May; 145():105014. PubMed ID: 33689805
[TBL] [Abstract][Full Text] [Related]
15. Dimethyl fumarate attenuates 2-VO-induced vascular dementia via activating the Nrf2 signaling pathway in rats.
Dhaliwal N; Dhaliwal J; Singh A; Chopra K
Inflammopharmacology; 2021 Apr; 29(2):537-547. PubMed ID: 33459879
[TBL] [Abstract][Full Text] [Related]
16. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
17. Protection of Male Rat Offspring against Hypertension Programmed by Prenatal Dexamethasone Administration and Postnatal High-Fat Diet with the Nrf2 Activator Dimethyl Fumarate during Pregnancy.
Hsu CN; Lin YJ; Yu HR; Lin IC; Sheen JM; Huang LT; Tain YL
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31416234
[TBL] [Abstract][Full Text] [Related]
18. Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease.
Kaidery NA; Banerjee R; Yang L; Smirnova NA; Hushpulian DM; Liby KT; Williams CR; Yamamoto M; Kensler TW; Ratan RR; Sporn MB; Beal MF; Gazaryan IG; Thomas B
Antioxid Redox Signal; 2013 Jan; 18(2):139-57. PubMed ID: 22746536
[TBL] [Abstract][Full Text] [Related]
19. Dimethyl fumarate confers neuroprotection by casein kinase 2 phosphorylation of Nrf2 in murine intracerebral hemorrhage.
Iniaghe LO; Krafft PR; Klebe DW; Omogbai EKI; Zhang JH; Tang J
Neurobiol Dis; 2015 Oct; 82():349-358. PubMed ID: 26176793
[TBL] [Abstract][Full Text] [Related]
20. Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1.
Innamorato NG; Jazwa A; Rojo AI; García C; Fernández-Ruiz J; Grochot-Przeczek A; Stachurska A; Jozkowicz A; Dulak J; Cuadrado A
PLoS One; 2010 Jul; 5(7):e11838. PubMed ID: 20676377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
